At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 95 enrolled
Drug / intervention
Budesonide +3 moredrug
Likely dose
Budesonide 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Emergency Department (ED) Use of Nebulized Budesonide as an Adjunct to Standardized Therapy in Acutely Ill Adults With Refractory Asthma: a Randomized, Double-blinded, Placebo-controlled Trial
In Brief
A Phase 3 clinical trial evaluating Budesonide, albuterol, and 2 other interventions for Asthma. Completed, enrolled 95 participants across 3 sites.
Detailed Summary
To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED patients with refractory acute asthma helps improve forced expiratory volume at one second (FEV1) and decrease the need for hospitalization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsAstraZeneca, Jacobi Medical Center, Nassau University Medical Center
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedJan 2008
Primary CompletionDec 2009
TodayJul 2026
First PostedJan 8, 2008
Enrollment StartSep 1, 2007
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.5 years ago
Interventions
Budesonidedrug
2mg/dose by nebulizer, four doses over 3 hours
albuteroldrug
2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromidedrug
2.5 mg, one dose
Prednisonedrug
60mg PO